PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33236793-2	2021	CASE DESCRIPTION: A 20-month-old, 12 kg, female with invasive MRSA infection presented with high-level ceftaroline resistance with no previous ceftaroline exposure.	T 91825	103-114	immunoglobulin kappa variable 1-27	Homo sapiens	18-22
34826629-0	2021	Successful treatment with daptomycin and ceftaroline of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) endocarditis: a case report.	T 91825	41-52	mitochondrial antiviral signaling protein	Homo sapiens	117-122
34462863-3	2021	Ceftaroline fosamil, a beta-lactam with broad-spectrum in vitro activity against Gram-positive pathogens (including MRSA and multidrug-resistant Streptococcus pneumoniae) and common Gram-negative organisms, is approved in the European Union and the United States for children with CAP/CABP or cSSTI/ABSSSI.	T 91825	0-11	S100 calcium binding protein G	Homo sapiens	285-289
34201722-3	2021	A secondary objective was to describe the rate of favorable clinical response in patients with bloodstream infections (BSI) due to methicillin-resistant Staphylococcus aureus (MRSA-BSI) receiving ceftaroline.	T 91825	196-207	solute carrier family 9 member A6	Homo sapiens	176-180
34201722-7	2021	Among patients with MRSA-BSI, ceftaroline was used as a first-line therapy and salvage therapy in 25% (3/12) and 75% (9/12) of cases, respectively, and as a monotherapy or in combination with daptomycin in 58% (7/12) and 42% (5/12) of patients, respectively.	T 91825	30-41	solute carrier family 9 member A6	Homo sapiens	20-24
34201722-10	2021	The use of ceftaroline for MRSA-BSI, either as a monotherapy or in combination with other anti-MRSA agents, showed promising rates of favorable response.	T 91825	11-22	solute carrier family 9 member A6	Homo sapiens	27-31
34201722-10	2021	The use of ceftaroline for MRSA-BSI, either as a monotherapy or in combination with other anti-MRSA agents, showed promising rates of favorable response.	T 91825	11-22	solute carrier family 9 member A6	Homo sapiens	95-99
34022417-9	2021	Susceptibility of extended-spectrum beta-lactamase (ESBL)-negative Escherichia coli to ceftaroline ranged from 67.0% in Asia/SP to 91.0% in Africa/ME; susceptibility to amikacin, meropenem and tigecycline was >=96.7% in all regions.	T 91825	87-98	EsbL	Escherichia coli	18-50
35498222-5	2022	The network meta-analysis showed that ceftaroline, ceftobiprole, delafloxacin and tigecycline had similar efficacy in the indirect comparisons (Ceftaroline Odds Ratio (OR) = 1.2, 95% Crl = 0.46-3.6), ceftobiprole (OR = 1.3, 95% Crl = 0.34-3.0) and tigecycline (OR = 0.96, 95% Crl = 0.30-2.9)).	T 91825	38-49	interleukin 31 receptor A	Homo sapiens	183-186
35498222-5	2022	The network meta-analysis showed that ceftaroline, ceftobiprole, delafloxacin and tigecycline had similar efficacy in the indirect comparisons (Ceftaroline Odds Ratio (OR) = 1.2, 95% Crl = 0.46-3.6), ceftobiprole (OR = 1.3, 95% Crl = 0.34-3.0) and tigecycline (OR = 0.96, 95% Crl = 0.30-2.9)).	T 91825	38-49	interleukin 31 receptor A	Homo sapiens	228-231
35498222-5	2022	The network meta-analysis showed that ceftaroline, ceftobiprole, delafloxacin and tigecycline had similar efficacy in the indirect comparisons (Ceftaroline Odds Ratio (OR) = 1.2, 95% Crl = 0.46-3.6), ceftobiprole (OR = 1.3, 95% Crl = 0.34-3.0) and tigecycline (OR = 0.96, 95% Crl = 0.30-2.9)).	T 91825	38-49	interleukin 31 receptor A	Homo sapiens	276-279
34965287-10	2022	Mesenchymal stem cells combined with ceftaroline reduced interleukin-8 lung concentrations (665 (595 to 795) vs. 804 (753 to 868) pg/g of lung; P = 0.007) compared to ceftaroline alone.	T 91825	37-48	interleukin-8	Oryctolagus cuniculus	57-70
33609718-2	2021	Combination therapy with daptomycin and ceftaroline (DAP+CPT) represents a novel therapeutic approach to MRSA BSI due to synergistic bactericidal activity.	T 91825	40-51	death associated protein	Homo sapiens	53-56
28720485-8	2017	Ceftaroline counteracted the effects of CSE on HBD2 release in differentiated THP-1.	T 91825	0-11	defensin beta 4A	Homo sapiens	47-51
33360831-8	2021	Furthermore, binding free energy calculations suggested the community-acquired bacterial pneumonia drug ceftaroline fosamil and the hepatitis C virus (HCV) protease inhibitor telaprevir are potent inhibitors against Mpro.	T 91825	104-115	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	216-220
33360831-11	2021	We suggest the telaprevir derivatives and ceftaroline fosamil bind tightly with SARS-CoV-2 Mpro and should be validated through preclinical testing.	T 91825	42-53	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	91-95
33207274-6	2021	Among MRSA isolates from IE (n = 115; MIC50/90, 1/2 mg/L), ceftaroline susceptibility was 98.0% in North America, 90.9% in LATAM-APAC, and 68.5% in Europe.	T 91825	59-70	growth differentiation factor 15	Homo sapiens	38-51
33258796-2	2020	Ceftaroline is a fifth generation cephalosporin binding and inhibiting penicillin binding protein (PBP2a).	T 91825	0-11	AT695_RS11765	Staphylococcus aureus	71-97
31504321-2	2020	Among 28 patients with eGFR<30 who received >=5 days of ceftaroline, we report three cases of encephalopathy.	T 91825	62-73	epidermal growth factor receptor	Homo sapiens	23-27
30726929-0	2019	Genomic characterization of inpatient evolution of MRSA resistant to daptomycin, vancomycin and ceftaroline.	T 91825	96-107	solute carrier family 9 member A6	Homo sapiens	51-55
30535190-3	2019	OBJECTIVES: To investigate ceftaroline CSF pharmacokinetics in ICU patients with an external ventricular drain (EVD).	T 91825	27-38	colony stimulating factor 2	Homo sapiens	39-42
30535190-13	2019	CONCLUSIONS: Ceftaroline CSF concentrations are too low to ensure prophylactic protection against most pathogens with MICs between 1 and 2 mg/L, owing to its limited central distribution.	T 91825	13-24	colony stimulating factor 2	Homo sapiens	25-28
30755518-6	2019	Treatment of THP-1 human macrophages infected with three different M. abscessus clinical isolates supported the in vitro findings, as the combination of 100 microg/ml ceftazidime and 0.125 microg/ml ceftaroline or 100 microg/ml ceftazidime and 0.25 microg/ml imipenem dramatically reduced the CFU counts to near baseline levels of infection.	T 91825	199-210	GLI family zinc finger 2	Homo sapiens	13-18
30755518-9	2019	Our recent discoveries that dual beta-lactams, specifically the combination of ceftazidime with ceftaroline or ceftazidime with imipenem, have significant in vitro MIC values and kill curve activities and are effective against infected THP-1 human macrophages provide optimism for a dual beta-lactam treatment strategy against MABC infections.	T 91825	96-107	GLI family zinc finger 2	Homo sapiens	236-241
33373731-9	2021	Rates of susceptibility to ceftaroline for ESBL-negative Escherichia coli (n = 442), Klebsiella pneumoniae (n = 381), and Klebsiella oxytoca (n = 103) were 92.1%, 93.2%, and 96.1%, respectively.	T 91825	27-38	EsbL	Escherichia coli	43-47
31938716-1	2020	Background: Daptomycin and ceftaroline (DAP-CPT) have been used for persistent methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), but have rarely been compared with other therapies.	T 91825	27-38	death associated protein	Homo sapiens	40-43
31857898-2	2019	Synergy observed in vitro between ceftaroline (CPT) and daptomycin (DAP) or vancomycin (VAN) may translate into clinical benefit.	T 91825	34-45	choline phosphotransferase 1	Homo sapiens	47-50
29941637-0	2018	Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus.	T 91825	0-11	AT695_RS11765	Staphylococcus aureus	57-83
28720485-8	2017	Ceftaroline counteracted the effects of CSE on HBD2 release in differentiated THP-1.	T 91825	0-11	GLI family zinc finger 2	Homo sapiens	78-83
28348157-11	2017	By lowering MICs to <=2 mg/liter, the ceftaroline-AVI combination could represent a favorable therapeutic option against Enterobacteriaceae expressing blaPER-2 Our studies define the inactivation of the PER-2 ESBL by AVI and suggest that the biophysical properties of the active site contribute to determining the efficiency of inactivation.	T 91825	41-52	period circadian regulator 2	Homo sapiens	157-162
27530754-8	2016	The IRR incidence was 22% for ceftaroline patients and 30% for vancomycin patients; OR = 0.66 (95% CI = 0.27-1.62; P = 0.362).	T 91825	30-41	insulin receptor related receptor	Homo sapiens	4-7
28314920-5	2017	In part, only expert opinions are given due to lack of study results.The two 5th generation cephalosporins ceftaroline and ceftobiprole have beside their equivalent efficacy to ceftriaxone (ceftaroline) and cefipim (ceftobiprole) high activity against MRSA.	T 91825	107-118	solute carrier family 9 member A6	Homo sapiens	252-256
28069651-6	2017	The hydrolysis of amoxicillin and nitrocefin by KPC-2 and CTX-M-15 was moderately affected by the substitution N132G, but that of ceftazidime, ceftaroline, and aztreonam was drastically reduced.	T 91825	143-154	UBA domain containing 1	Homo sapiens	48-53
27397760-7	2016	The effects of ceftaroline on HBD2 protein and on IL-8 mRNA were confirmed in primary bronchial epithelial cells.	T 91825	15-26	defensin beta 4A	Homo sapiens	30-34
27397760-8	2016	In conclusion, ceftaroline is able to counteract the effects of CSE on the innate immunity and pro-inflammatory responses modulating TLR2, LPS binding, NFkB activation and activity, HBD2 and IL-8 expression in bronchial epithelial cells.	T 91825	15-26	choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity)	Homo sapiens	64-67
27397760-8	2016	In conclusion, ceftaroline is able to counteract the effects of CSE on the innate immunity and pro-inflammatory responses modulating TLR2, LPS binding, NFkB activation and activity, HBD2 and IL-8 expression in bronchial epithelial cells.	T 91825	15-26	toll like receptor 2	Homo sapiens	133-137
27397760-8	2016	In conclusion, ceftaroline is able to counteract the effects of CSE on the innate immunity and pro-inflammatory responses modulating TLR2, LPS binding, NFkB activation and activity, HBD2 and IL-8 expression in bronchial epithelial cells.	T 91825	15-26	defensin beta 4A	Homo sapiens	182-186
27397760-8	2016	In conclusion, ceftaroline is able to counteract the effects of CSE on the innate immunity and pro-inflammatory responses modulating TLR2, LPS binding, NFkB activation and activity, HBD2 and IL-8 expression in bronchial epithelial cells.	T 91825	15-26	C-X-C motif chemokine ligand 8	Homo sapiens	191-195
25977400-0	2015	Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia.	T 91825	22-33	solute carrier family 9 member A6	Homo sapiens	74-78
27397760-6	2016	Ceftaroline counteracted the CSE effect on TLR2 expression, on LPS binding, on IL-8 mRNA, HBD2 and NFkB in 16HBE.	T 91825	0-11	choreoathetosis/spasticity, episodic (paroxysmal choreoathetosis/spasticity)	Homo sapiens	29-32
27397760-6	2016	Ceftaroline counteracted the CSE effect on TLR2 expression, on LPS binding, on IL-8 mRNA, HBD2 and NFkB in 16HBE.	T 91825	0-11	toll like receptor 2	Homo sapiens	43-47
27397760-6	2016	Ceftaroline counteracted the CSE effect on TLR2 expression, on LPS binding, on IL-8 mRNA, HBD2 and NFkB in 16HBE.	T 91825	0-11	C-X-C motif chemokine ligand 8	Homo sapiens	79-83
27397760-6	2016	Ceftaroline counteracted the CSE effect on TLR2 expression, on LPS binding, on IL-8 mRNA, HBD2 and NFkB in 16HBE.	T 91825	0-11	defensin beta 4A	Homo sapiens	90-94
25422288-0	2015	Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis.	T 91825	0-11	colony stimulating factor 2	Homo sapiens	12-15
25246437-1	2015	OBJECTIVES: We previously demonstrated that ceftaroline enhances daptomycin against MRSA in vitro.	T 91825	44-55	solute carrier family 9 member A6	Homo sapiens	84-88
25246437-10	2015	CONCLUSIONS: These findings confirm that ceftaroline+daptomycin is a potent combination against MRSA.	T 91825	41-52	solute carrier family 9 member A6	Homo sapiens	96-100
25246437-0	2015	The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.	T 91825	19-30	solute carrier family 9 member A6	Homo sapiens	115-119
25147169-5	2014	At the start of ceftaroline therapy, the patient"s baseline absolute neutrophil count (ANC) was 6640 cells/muL and decreased to 816 cells/muL by day 19, eventually falling to 0 cells/muL on day 21 of therapy.	T 91825	16-27	tripartite motif containing 37	Homo sapiens	107-110
25147169-5	2014	At the start of ceftaroline therapy, the patient"s baseline absolute neutrophil count (ANC) was 6640 cells/muL and decreased to 816 cells/muL by day 19, eventually falling to 0 cells/muL on day 21 of therapy.	T 91825	16-27	tripartite motif containing 37	Homo sapiens	138-141
25147169-5	2014	At the start of ceftaroline therapy, the patient"s baseline absolute neutrophil count (ANC) was 6640 cells/muL and decreased to 816 cells/muL by day 19, eventually falling to 0 cells/muL on day 21 of therapy.	T 91825	16-27	tripartite motif containing 37	Homo sapiens	138-141
24529941-6	2014	Ceftaroline-avibactam was very active against Escherichia coli and Klebsiella pneumoniae (MIC50/90, 0.03/0.06 and 0.06/0.25 mug/mL, respectively) including extended-spectrum beta-lactamase (ESBL) screen-positive phenotypes (MIC50/90, 0.06/0.12 and 0.12/1 mug/mL, respectively).	T 91825	0-11	EsbL	Escherichia coli	190-194
25222304-15	2014	Ceftaroline exhibited good activity against non-ESBL phenotype strains of E. coli and Klebsiella spp.	T 91825	0-11	EsbL	Escherichia coli	48-52
25222304-17	2014	CONCLUSION: Ceftaroline demonstrated potent in vitro activity when tested against S. aureus, S. pneumoniae, H. influenzae, beta-hemolytic streptococci and non-ESBL-phenotype E. coli and Klebsiella spp.	T 91825	12-23	EsbL	Escherichia coli	159-163
24529941-9	2014	Ceftaroline-avibactam exhibited a broad-spectrum of in vitro activity against isolates from patients in the USA with ABSSSI including MRSA, beta-hemolytic streptococci, E. coli, and K. pneumoniae as well as ESBL screen-positive phenotype isolates and merits further study in clinical indications where these resistant organisms may be a concern.	T 91825	0-11	EsbL	Escherichia coli	207-211
19441869-2	2009	Ceftaroline has the ability to bind to penicillin-binding protein (PBP)2a, an MRSA-specific PBP that has low affinity for most other beta-lactam antibacterials.	T 91825	0-11	phosphatidylethanolamine binding protein 1	Homo sapiens	67-70
24247138-10	2014	The overall rate of ceftaroline susceptibility in the current study was 99.4% (one hVISA isolate had an intermediate ceftaroline MIC).	T 91825	20-31	mitochondrial antiviral signaling protein	Homo sapiens	83-88
24247138-10	2014	The overall rate of ceftaroline susceptibility in the current study was 99.4% (one hVISA isolate had an intermediate ceftaroline MIC).	T 91825	117-128	mitochondrial antiviral signaling protein	Homo sapiens	83-88
24366742-5	2014	Consistent with the observed biophysical changes, ceftaroline resulted in increased binding and killing of daptomycin-nonsusceptible VRE by human cathelicidin LL37.	T 91825	50-61	cathelicidin antimicrobial peptide	Homo sapiens	159-163
23188792-0	2013	Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.	T 91825	12-23	GLI family zinc finger 2	Homo sapiens	73-78
22441578-6	2012	For one, from an CTX-M-15-positive Escherichia coli, the ceftaroline + avibactam MIC was raised, but the organism had reduced resistance to ceftaroline and lost resistance to other oxyimino-cephalosporins, with this profile retained when the mutant bla(CTX-M-15) was cloned into E. coli DH5alpha.	T 91825	57-68	hypothetical protein	Escherichia coli	17-25
22441578-6	2012	For one, from an CTX-M-15-positive Escherichia coli, the ceftaroline + avibactam MIC was raised, but the organism had reduced resistance to ceftaroline and lost resistance to other oxyimino-cephalosporins, with this profile retained when the mutant bla(CTX-M-15) was cloned into E. coli DH5alpha.	T 91825	57-68	hypothetical protein	Escherichia coli	253-261
22441578-6	2012	For one, from an CTX-M-15-positive Escherichia coli, the ceftaroline + avibactam MIC was raised, but the organism had reduced resistance to ceftaroline and lost resistance to other oxyimino-cephalosporins, with this profile retained when the mutant bla(CTX-M-15) was cloned into E. coli DH5alpha.	T 91825	140-151	hypothetical protein	Escherichia coli	17-25
24217694-0	2014	In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.	T 91825	58-69	mitochondrial antiviral signaling protein	Homo sapiens	99-104
24217694-0	2014	In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.	T 91825	58-69	mitochondrial antiviral signaling protein	Homo sapiens	100-104
23422917-2	2013	Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively.	T 91825	53-64	mitochondrial antiviral signaling protein	Homo sapiens	96-100
23422917-2	2013	Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively.	T 91825	53-64	mitochondrial antiviral signaling protein	Homo sapiens	112-117
23422917-2	2013	Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively.	T 91825	53-64	mitochondrial antiviral signaling protein	Homo sapiens	113-117
23422917-2	2013	Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively.	T 91825	53-64	mitochondrial antiviral signaling protein	Homo sapiens	153-158
23070161-6	2013	Ceftaroline exposure enhanced daptomycin-induced depolarization (81.7% versus 72.3%; P = 0.03) and killing by cathelicidin LL37 (P < 0.01) and reduced cell wall thickness (P < 0.001).	T 91825	0-11	cathelicidin antimicrobial peptide	Homo sapiens	123-127
22398650-6	2012	Penicillin-binding protein (PBP) affinities for ceftaroline and comparators were determined.	T 91825	48-59	AT695_RS11765	Staphylococcus aureus	0-26
22398650-6	2012	Penicillin-binding protein (PBP) affinities for ceftaroline and comparators were determined.	T 91825	48-59	AT695_RS11765	Staphylococcus aureus	28-31
21976769-10	2011	All hVISA isolates were susceptible to linezolid, tigecycline, and ceftaroline.	T 91825	67-78	mitochondrial antiviral signaling protein	Homo sapiens	4-9
21576444-1	2011	Ceftaroline (CPT) is a new cephalosporin exhibiting bactericidal activity against Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae (MDRSP), as well as common Gram-negative pathogens.	T 91825	0-11	choline phosphotransferase 1	Homo sapiens	13-16
20346632-7	2010	In contrast, the combination of ceftaroline plus tobramycin at 0.5 x MIC was synergistic against the two MRSA strains and the hVISA but was indifferent against the VISA isolate.	T 91825	32-43	mitochondrial antiviral signaling protein	Homo sapiens	126-131
20346632-7	2010	In contrast, the combination of ceftaroline plus tobramycin at 0.5 x MIC was synergistic against the two MRSA strains and the hVISA but was indifferent against the VISA isolate.	T 91825	32-43	mitochondrial antiviral signaling protein	Homo sapiens	127-131
19349512-2	2009	However, the activity of ceftaroline cannot be solely relied upon for eradication of multidrug-resistant gram-negative isolates, such as Pseudomonas aeruginosa and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, which represent a current clinical concern.	T 91825	25-36	EsbL	Escherichia coli	198-202
19349512-6	2009	Ceftaroline exhibited a MIC range of 0.125 to 1,024 microg/ml and was reduced 2- to 512-fold by combination with tazobactam (4 microg/ml) for ESBL-producing strains.	T 91825	0-11	EsbL	Escherichia coli	142-146
19441869-2	2009	Ceftaroline has the ability to bind to penicillin-binding protein (PBP)2a, an MRSA-specific PBP that has low affinity for most other beta-lactam antibacterials.	T 91825	0-11	phosphatidylethanolamine binding protein 1	Homo sapiens	92-95